Nuclear Transport Modulators for Inflammatory Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-inflammatory therapeutics, such as steroidal and non-steroidal anti-inflammatory drugs, have significant side effects and are not adequately effective in treating inflammatory diseases like psoriasis, lupus, rheumatoid arthritis, and diabetes.
Innovation Solution
The use of importin beta-selective and importin alpha-selective Nuclear Transport Modifiers (NTMs) to modulate nuclear transport mediated by nuclear import shuttles, thereby suppressing the inflammatory basis of diseases. These NTMs include cell-penetrating peptides, peptide mimetics, nucleic acids, or small molecules that specifically bind to importins alpha and beta.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional anti-inflammatory drugs (steroidal and non-steroidal) are used to treat inflammatory diseases, then inflammation is suppressed, but significant side effects occur
Solution Approach 1:
The patent uses importin beta-selective nuclear transport modifiers as intermediary molecules that specifically target nuclear import shuttles to prevent transcription factor nuclear translocation. This intermediary approach selectively interrupts the inflammatory signaling pathway at the nuclear transport level without affecting other cellular processes, thereby achieving anti-inflammatory effects with reduced side effects compared to conventional drugs
Solution Approach 2:
The invention extracts and targets the specific mechanism of nuclear import shuttles (importin beta) that mediate the nuclear translocation of transcription factors involved in inflammation. By isolating and targeting this specific transport mechanism rather than broadly suppressing inflammation, the treatment achieves efficacy while minimizing off-target side effects
2Object-affected harmful factors
If conventional anti-inflammatory drugs are used to treat inflammatory diseases, then inflammation is reduced, but effectiveness is insufficient for severe cases
Solution Approach 1:
The patent employs nuclear transport modifiers that act preliminarily by blocking the nuclear import of transcription factors before they can initiate inflammatory gene expression. This upstream intervention prevents the inflammatory cascade from fully developing, providing more effective control of severe inflammation compared to conventional drugs that act downstream
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The described approach provides a treatment option that is free from certain side effects associated with conventional anti-inflammatory drugs, effectively reducing inflammation and modulating the entry of transcription factors into the nucleus, thus treating inflammatory diseases.
Implementation Method 1
modulate nuclear transport mediated by nuclear import shuttles
Implementation Method 2
NTMs include cell-penetrating peptides, peptide mimetics, nucleic acids, or small molecules that specifically bind to importins alpha and beta
Data Source
AI summary
The present invention relates to compositions and methods for treating autoimmune, microbial, metabolic, neoplastic, and posttraumatic diseases mediated by inflammation in a subject. Compositions and methods including at least one importin beta-selective nuclear transport modifier (NTM) and/or at least one importin alpha-selective NTM, and/or at least one importin alpha-specific NTM, and/or at least one inhibitor of importin alpha and importin beta complex formation may be administered to a subject to modulate the transport of transcription factors, mediated by nuclear import adaptors, into the nucleus of a cell resulting in a decrease or abrogation of inflammation.